Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Cell Cycle/Checkpoint >> PLK

PLK

PLK (Polo-like kinase 1) is a serine/threonine-protein that are implicated in cell cycle, mitosis, cytokinesis and DNA damage etc.

Products for  PLK

  1. Cat.No. Product Name Information
  2. GC62728 (1E)-CFI-400437 dihydrochloride (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity. (1E)-CFI-400437 dihydrochloride Chemical Structure
  3. GC14186 3MB-PP1 polo-like kinase 1 (Plk1) allele inhibitor,ATP-competitive 3MB-PP1 Chemical Structure
  4. GC35216 AAPK-25 AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. AAPK-25 Chemical Structure
  5. GC73375 Aurora Kinases-IN-3 Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB. Aurora Kinases-IN-3 Chemical Structure
  6. GC11224 BI6727(Volasertib)

    BI 6727; BI-6727

     BI6727(Volasertib) (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. BI6727(Volasertib) inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. BI6727(Volasertib) induces mitotic arrest and apoptosis. BI6727(Volasertib), a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models. BI6727(Volasertib) Chemical Structure
  7. GC32688 Centrinone (LCR-263)

    LCR-263

     Centrinone (LCR-263) (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a Ki of 0.16 nM. Centrinone (LCR-263) Chemical Structure
  8. GC32751 Centrinone-B (LCR-323)

    LCR-323

     Centrinone-B (LCR-323) (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM. Centrinone-B (LCR-323) Chemical Structure
  9. GC13606 CFI-400945

    orally available, selective inhibitor of polo-like kinase 4 (PLK4)

     CFI-400945 Chemical Structure
  10. GC35660 CFI-400945 free base CFI-400945 free base Chemical Structure
  11. GC13268 Cyclapolin 9 PLK1 inhibitor Cyclapolin 9 Chemical Structure
  12. GC74280 Dihydrobaicalein Didrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM. Dihydrobaicalein Chemical Structure
  13. GC12335 GSK461364

    GSK461364A

     Plk1 inhibitor GSK461364 Chemical Structure
  14. GC49280 GSK579289A A Plk1 inhibitor GSK579289A Chemical Structure
  15. GC11621 GW843682X A reversible polo-like kinase inhibitor GW843682X Chemical Structure
  16. GC13928 HMN-214

    IVX-214

     Plk inhibitor,broad-spectrum anti-tumor agent HMN-214 Chemical Structure
  17. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13 Chemical Structure
  18. GC69379 Lipid 8

    Lipid 8 is an ionizable amino lipid that can be used for synthesizing lipid nanoparticles.

     Lipid 8 Chemical Structure
  19. GC10163 MLN0905 Potent PLK1 inhibitor MLN0905 Chemical Structure
  20. GC15745 Mps1-IN-2 Mps1 kinase inhibitor Mps1-IN-2 Chemical Structure
  21. GC12515 NMS-1286937

    NMS-P937, Onvansertib, PCM-075

     NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM. NMS-1286937 Chemical Structure
  22. GC62174 ON1231320 ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 ?M. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity. ON1231320 Chemical Structure
  23. GC73885 PLK1/BRD4-IN-3 PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 Chemical Structure
  24. GC73773 PLK1/BRD4-IN-5 PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 Chemical Structure
  25. GC65189 PLK4-IN-1 PLK4-IN-1 (Example A6) is a PLK4 inhibitor, with an IC50 of ≤ 0.1 μM. PLK4-IN-1 Chemical Structure
  26. GC72983 PLK4-IN-4 PLK4-IN-4 (compound 22) is a potent PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-4 Chemical Structure
  27. GC69718 Plogosertib

    CYC140

    Plogosertib (CYC140) is a selective, potent, orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity and can be used for research on various tumors including esophageal cancer, gastric cancer, leukemia, non-small cell lung cancer, ovarian cancer and squamous cell carcinoma.

     Plogosertib Chemical Structure
  28. GC60294 Poloppin Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9?μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5?μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis.?Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors. Poloppin Chemical Structure
  29. GC14735 Poloxime polo-like kinase 1 （PLK) analogue Poloxime Chemical Structure
  30. GC13543 Poloxin An inhibitor of the Plk1 polo-box domain Poloxin Chemical Structure
  31. GC12415 Rigosertib

    PI3K/PLK1 inhibitor

     Rigosertib Chemical Structure
  32. GC14358 Rigosertib (ON-01910,Estybon)

    Rigosertib

     Plk1 inhibitor Rigosertib (ON-01910,Estybon) Chemical Structure
  33. GC13580 Rigosertib sodium

    Non-ATP-competitive inhibitor of PLK1

     Rigosertib sodium Chemical Structure
  34. GC13903 Ro3280 PLK1 inhibitor,potent and highly selective Ro3280 Chemical Structure
  35. GC14644 SBE 13 HCl SBE 13 HCl is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE 13 HCl poorly inhibits Plk2 (IC50>66μM) or Plk3 (IC50=875nM). SBE 13 HCl Chemical Structure
  36. GC37601 SBE13 SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66?μM) or Plk3 (IC50=875?nM). SBE13 Chemical Structure
  37. GC73230 SP27 SP27 is a PROTAC that can selective degrades PLK4, with a DC50 of 19.5 nM. SP27 Chemical Structure
  38. GC37725 TAK-960 dihydrochloride TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts. TAK-960 dihydrochloride Chemical Structure
  39. GC37726 TAK-960 hydrochloride TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts. TAK-960 hydrochloride Chemical Structure
  40. GC10773 TAK960

    Oral and selective PLK1 inhibitor

     TAK960 Chemical Structure
  41. GC16771 TC-S 7005 polo-like kinase 2 (PLK2) inhibitor TC-S 7005 Chemical Structure
  42. GC12338 Wortmannin

    KY 12420

     Wortmannin is a highly potent direct inhibitor of PI3-kinase specificity originally derived from fungi. Wortmannin Chemical Structure

41 Item(s)

per page

Set Descending Direction